Cargando…
Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the object...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928183/ https://www.ncbi.nlm.nih.gov/pubmed/36798486 http://dx.doi.org/10.3389/fendo.2022.1034580 |
_version_ | 1784888600823857152 |
---|---|
author | Mughal, M. Zulf Baroncelli, Giampiero I. de Lucas-Collantes, Carmen Linglart, Agnès Magnolato, Andrea Raimann, Adalbert Santos, Fernando Schnabel, Dirk Shaw, Nick Nilsson, Ola |
author_facet | Mughal, M. Zulf Baroncelli, Giampiero I. de Lucas-Collantes, Carmen Linglart, Agnès Magnolato, Andrea Raimann, Adalbert Santos, Fernando Schnabel, Dirk Shaw, Nick Nilsson, Ola |
author_sort | Mughal, M. Zulf |
collection | PubMed |
description | Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions via Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt rickets despite conventional treatment being eligible. We initiated burosumab dosing according to guidance in the Summary of Product Characteristics, an international consensus statement from 2019 and local country guidelines. Dose titration was primarily guided by serum phosphate levels, with some centers also using the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). We monitored response to burosumab treatment clinically (growth, deformities, bone pain and physical functioning), radiologically (rickets and deformities) and biochemically (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, urine calcium-creatinine ratio and TmP/GFR). Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood. |
format | Online Article Text |
id | pubmed-9928183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99281832023-02-15 Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries Mughal, M. Zulf Baroncelli, Giampiero I. de Lucas-Collantes, Carmen Linglart, Agnès Magnolato, Andrea Raimann, Adalbert Santos, Fernando Schnabel, Dirk Shaw, Nick Nilsson, Ola Front Endocrinol (Lausanne) Endocrinology Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab treatment in clinical practice, we convened with the objective of sharing these practice-based insights on the use of burosumab in children and adolescents with XLH. We attended two virtual meetings, then discussed key questions via Within3, a virtual online platform. Points of discussion related to patient selection criteria, burosumab starting dose, dose titration and treatment monitoring. Our discussions revealed that criteria for selecting children with XLH varied across Europe from all children above 1 year to only children with overt rickets despite conventional treatment being eligible. We initiated burosumab dosing according to guidance in the Summary of Product Characteristics, an international consensus statement from 2019 and local country guidelines. Dose titration was primarily guided by serum phosphate levels, with some centers also using the ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR). We monitored response to burosumab treatment clinically (growth, deformities, bone pain and physical functioning), radiologically (rickets and deformities) and biochemically (serum phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, urine calcium-creatinine ratio and TmP/GFR). Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood. Frontiers Media S.A. 2023-01-31 /pmc/articles/PMC9928183/ /pubmed/36798486 http://dx.doi.org/10.3389/fendo.2022.1034580 Text en Copyright © 2023 Mughal, Baroncelli, de Lucas-Collantes, Linglart, Magnolato, Raimann, Santos, Schnabel, Shaw and Nilsson https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Mughal, M. Zulf Baroncelli, Giampiero I. de Lucas-Collantes, Carmen Linglart, Agnès Magnolato, Andrea Raimann, Adalbert Santos, Fernando Schnabel, Dirk Shaw, Nick Nilsson, Ola Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title | Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title_full | Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title_fullStr | Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title_full_unstemmed | Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title_short | Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries |
title_sort | burosumab for x-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven european countries |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928183/ https://www.ncbi.nlm.nih.gov/pubmed/36798486 http://dx.doi.org/10.3389/fendo.2022.1034580 |
work_keys_str_mv | AT mughalmzulf burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT baroncelligiampieroi burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT delucascollantescarmen burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT linglartagnes burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT magnolatoandrea burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT raimannadalbert burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT santosfernando burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT schnabeldirk burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT shawnick burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries AT nilssonola burosumabforxlinkedhypophosphatemiainchildrenandadolescentsopinionbasedonearlyexperienceinseveneuropeancountries |